RE: Gsk, the market, life23 Oct 2020 10:16
Hi Fat,
I see you say net debt is about £25 billion, I assume you mean current liabilities. I thought it was worth exploring this as you are absolutely right that even in 2015 current liabilities were only a meager £13 billion.
So that is a doubling of debt in 5 years.
However, in that time revenues have also grown, from £23billion to £33 billion a 43% increase. So debt as a proportion of revenue has not grown as much as rapidly.
in 2015 current liabilities were 56% of revenues
In 2019 current liabilities are 77% of revenues
This is not great but when I compare to Astra Zenica I find that they have a similar debt to revenue ratio 18/24 = 74%.
The difference is that GSK profits have been starting to grow again in the last few years and both remain fairly steady in terms of cash on hand.
I would like to see GSK start to reduce debt, but probably unlikely in the current climate but if they can hold steady at the level and not add too much more debt there is no reason to worry just yet. If that increased debt leads to longer term growth in profits then that is good debt. If it just pays dividends then that would be a poor outcome.